CA19-9与K-ras基因突变联合检测诊断胰腺癌的价值  

Combined detections of CA19-9 and K-ras gene mutation for diagnosis of pancreatic cancer

作　　者：刘香吉[1] 刘福国[1] 赵洁[1] 刘世海[1] 江月萍[1] 

机构地区：[1]青岛大学医学院附属医院,山东青岛266003

出　　处：《山东医药》2014年第26期39-41,共3页Shandong Medical Journal

基　　金：青岛市软科学研究计划项目[11-2-3-(12)-nsh]

摘　　要：目的探讨外周血糖链抗原19-9(CA19-9)及胰腺癌组织K-ras基因突变联合检测早期诊断胰腺癌的价值。方法选择31例胰腺癌行手术治疗的患者作为胰腺癌组,22例胰腺良性病变行手术治疗的患者作为良性组。采用电化学发光法检测两组外周血CA19-9水平,比较外周血CA19-9阳性(>39 U/mL)率。采用突变等位基因特异性扩增(PCR-MASA)法检测两组病变组织K-ras基因12密码子点突变情况,计算K-ras基因突变率。计算CA19-9、K-ras基因突变单一检测及联合检测对胰腺癌的诊断效能。结果胰腺癌组CA19-9阳性率为74.2%(23/31),K-ras基因突变率为80.6%(25/31)。胰腺癌组CA19-9阳性率及K-ras基因突变率均明显高于良性组(P均<0.05);CA19-9与K-ras基因联合检测诊断胰腺癌的特异性、阳性预测值及诊断准确性均高于CA19-9与K-ras基因单一检测。结论 CA19-9与K-ras基因联合检测诊断早期胰腺癌的价值高于二者单一检测。Objective To investigate the effects of combined detections of carbohydrate antigen 19-9 （ CA19-9 ） and K-ras gene mutation for diagnosis of pancreatic cancer .Methods Thirty-one patients with pancreatic cancer undergoing surgery （ the pancreatic cancer group ） and 22 cases with pancreatic benign lesions undergoing surgery （ the benign group ） were selected .The CA19-9 level in the peripheral blood was detected by electrochemiluminescence and the positive （〉39 U/mL） rate of CA19-9 was calculated in the two groups; K-ras gene 12 codon mutations were detected by mutant allele-specific amplification （ PCR-MASA） and K-ras gene mutation rate was calculated .Results The CA19-9 positive rate and the K-ras gene mutation rate of pancreatic cancer group were significantly higher than those of the benign group （ all P〈0.05）.K-ras gene mutation rate was 80.6% （25/31）.The sensitivity, specificity, positive predictive value , negative predictive value and accuracy of combined detections of CA 19-9 and K-ras gene in diagnosis of pancreatic cancer were all higher than those of the single detection of CA 19-9 and K-ras gene .Conclusion The combined detections of CAl 9-9 and K-ras gene are more helpful in the early diagnosis of pancreatic cancer than the single detection .

关 键 词：胰腺肿瘤 K—ras基因 外周血糖链抗原19-9 联合检测 

分 类 号：R735.9[医药卫生—肿瘤]